Analysts’ Opinions Are Mixed on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX) and 10x Genomics (TXG)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vertex Pharmaceuticals (VRTX – Research Report) and 10x Genomics (TXG – Research Report).
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vertex Pharmaceuticals (VRTX)
Maxim Group analyst Naz Rahman maintained a Hold rating on Vertex Pharmaceuticals yesterday. The company’s shares closed last Friday at $491.47.
According to TipRanks.com, Rahman is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Vertex Pharmaceuticals is a Strong Buy with an average price target of $548.63, implying a 16.3% upside from current levels. In a report released today, TipRanks – Anthropic also downgraded the stock to Hold with a $507.00 price target.
See today’s best-performing stocks on TipRanks >>
10x Genomics (TXG)
In a report released yesterday, Tycho Peterson from Jefferies reiterated a Buy rating on 10x Genomics, with a price target of $21.00. The company’s shares closed last Friday at $18.12.
According to TipRanks.com, Peterson is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for 10x Genomics with a $19.64 average price target, which is a 2.1% upside from current levels. In a report released yesterday, Barclays also maintained a Buy rating on the stock with a $22.00 price target.
